13G Filing: Viking Global and Editas Medicine, Inc. (EDIT)

Page 1 of 20

As a new 13G filing with the US Securities and Exchange Commission showed, Andreas Halvorsen‘s Viking Global holds a long position in Editas Medicine Inc (NASDAQ:EDIT). The filing revealed that Viking Global holds a passive stake in the company, which contains 2.73 million shares of Editas. The holding amasses 7.5% of the company’s outstanding common stock. Editas Medicine went public and started trading last week.

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Viking Global Investors 0 2,729,808 0 2,729,808 2,729,808 7.5%
Viking Global Performance 0 753,625 0 753,625 753,625 2.1%
Viking Global Equities 0 256,986 0 256,986 256,986 0.7%
Viking Global Equities II 0 15,072 0 15,072 15,072 0.0%
VGE III Portfolio Ltd. 0 481,567 0 481,567 481,567 1.3%
Viking Long Fund GP 0 266,782 0 266,782 266,782 0.7%
Viking Long Fund Master Ltd. 0 266,782 0 266,782 266,782 0.7%
Viking Global Opportunities GP 0 1,709,401 0 1,709,401 1,709,401 4.7%
Viking Global Opportunities Portfolio GP 0 1,709,401 0 1,709,401 1,709,401 4.7%
Viking Global Opportunities Illiquid Investments Sub-Master 0 1,709,401 0 1,709,401 1,709,401 4.7%
O. Andreas Halvorsen 0 2,729,808 0 2,729,808 2,729,808 7.5%
David C. Ott 0 2,729,808 0 2,729,808 2,729,808 7.5%
Daniel S. Sundheim 0 2,729,808 0 2,729,808 2,729,808 7.5%

Follow Andreas Halvorsen's Viking Global

Page 1 of 20 SEC Filing

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________

Schedule 13G
________________

INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d-1(b),(c)
AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2
UNDER THE SECURITIES EXCHANGE ACT OF 1934*

Editas Medicine, Inc.
(Name of Issuer)

Common Stock
(Title of Class of Securities)

28106W103
(CUSIP Number)

February 8, 2016
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this
Schedule is filed:
[ ] Rule 13d-1(b)
[X] Rule 13d-1(c)
[ ] Rule 13d-1(d)

___________

* The remainder of this cover page shall be filled out for a reporting
person’s initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which
would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not
be deemed to be “filed” for the purpose of Section 18 of the Securities
Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that
section of the Act but shall be subject to all other provisions of the Act
(however, see the Notes).

Follow Editas Medicine Inc.

Page 1 of 20